WARNING: CONGESTIVE HEART FAILURE
- Thiazolidinediones, including ACTOS ®, cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1)].
- After initiation of ACTOS, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of ACTOS must be considered.
- ACTOS is not recommended in patients with symptomatic heart failure.
- Initiation of ACTOS in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated [see Contraindications (4) and Warnings and Precautions (5.1)]. WARNING: CONGESTIVE HEART FAILURE See full prescribing information for complete boxed warning.
- Thiazolidinediones, including ACTOS, cause or exacerbate congestive heart failure in some patients. (5.1)
- After initiation of ACTOS, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of ACTOS must be considered. (5.1)
- ACTOS is not recommended in patients with symptomatic heart failure. (5.1)
- Initiation of ACTOS in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated. (4, 5.1)
Use: Labeled indications
- Monotherapy and Combination Therapy ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14) ] .
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Monotherapy and Combination Therapy ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)]. Important Limitations of Use ACTOS exerts its antihyperglycemic effect only in the presence of endogenous insulin.
ACTOS should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see Warnings and Precautions (5.3)]. ACTOS is a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.
(1, 14) Important Limitations of Use:
- Not for treatment of type 1 diabetes or diabetic ketoacidosis. (1)
Contraindications
4 CONTRAINDICATIONS • Initiation in patients with established NYHA Class III or IV heart failure [see Boxed Warning]. • Use in patients with known hypersensitivity to pioglitazone or any other component of ACTOS. • Initiation in patients with established New York Heart Association (NYHA) Class III or IV heart failure [see Boxed Warning]. (4) • Use in patients with known hypersensitivity to pioglitazone or any other component of ACTOS. (4)
US FDA labelDosing: Adult
- • Initiate ACTOS at 15 mg or 30 mg once daily. Limit initial dose to 15 mg once daily in patients with NYHA Class I or II heart failure. (2.1)
- • If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily. (2.1)
- • Obtain liver tests before starting ACTOS. If abnormal, use caution when treating with ACTOS, investigate the probable cause, treat (if possible) and follow appropriately. Monitoring liver tests while on ACTOS is not recommended in patients without liver disease. (5.3)
2.1 Recommendations for All Patients
2.1 Recommendations for All Patients ACTOS should be taken once daily and can be taken without regard to meals. The recommended starting dose for patients without congestive heart failure is 15 mg or 30 mg once daily. The recommended starting dose for patients with congestive heart failure (NYHA Class I or II) is 15 mg once daily.
The dose can be titrated in increments of 15 mg up to a maximum of 45 mg once daily based on glycemic response as determined by HbA1c. After initiation of ACTOS or with dose increase, monitor patients carefully for adverse reactions related to fluid retention such as weight gain, edema, and signs and symptoms of congestive heart failure [see Boxed Warning and Warnings and Precautions (5.5)].
Liver tests (serum alanine and aspartate aminotransferases, alkaline phosphatase, and total bilirubin) should be obtained prior to initiating ACTOS. Routine periodic monitoring of liver tests during treatment with ACTOS is not recommended in patients without liver disease. Patients who have liver test abnormalities prior to initiation of ACTOS or who are found to have abnormal liver tests while taking ACTOS should be managed as described under Warnings and Precautions [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].
2.2 Concomitant
2.2 Concomitant Use with an Insulin Secretagogue or Insulin If hypoglycemia occurs in a patient co-administered ACTOS and an insulin secretagogue (e.g., sulfonylurea), the dose of the insulin secretagogue should be reduced. If hypoglycemia occurs in a patient co-administered ACTOS and insulin, the dose of insulin should be decreased by 10% to 25%.
Further adjustments to the insulin dose should be individualized based on glycemic response.
2.3 Concomitant Use with Strong CYP2C8 Inhibitors Coadministration
2.3 Concomitant Use with Strong CYP2C8 Inhibitors Coadministration of ACTOS and gemfibrozil, a strong CYP2C8 inhibitor, increases pioglitazone exposure approximately 3-fold. Therefore, the maximum recommended dose of ACTOS is 15 mg daily when used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
Dosing: Altered kidney function
Renal Impairment The serum elimination half-life of pioglitazone, M-III, and M-IV remains unchanged in patients with moderate (creatinine clearance [CLcr] 30 to 50 mL/min) and severe (CLcr <30 mL/min) renal impairment when compared to subjects with normal renal function. Therefore, no dose adjustment in patients with renal impairment is required.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of ACTOS in pediatric patients have not been established. ACTOS is not recommended for use in pediatric patients based on adverse effects observed in adults, including fluid retention and congestive heart failure, fractures, and urinary bladder tumors [see Warnings and Precautions (5.1, 5.4, 5.5, and 5.6)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use A total of 92 patients (15.2%) treated with ACTOS in the three pooled 16- to 26-week double-blind, placebo-controlled, monotherapy trials were ≥65 years old and two patients (0.3%) were ≥75 years old. In the two pooled 16- to 24-week add-on to sulfonylurea trials, 201 patients (18.7%) treated with ACTOS were ≥65 years old and 19 (1.8%) were ≥75 years old.
In the two pooled 16- to 24-week add-on to metformin trials, 155 patients (15.5%) treated with ACTOS were ≥65 years old and 19 (1.9%) were ≥75 years old. In the two pooled 16- to 24-week add-on to insulin trials, 272 patients (25.4%) treated with ACTOS were ≥65 years old and 22 (2.1%) were ≥75 years old. In PROactive, 1068 patients (41.0%) treated with ACTOS were ≥65 years old and 42 (1.6%) were ≥75 years old.
In pharmacokinetic studies with pioglitazone, no significant differences were observed in pharmacokinetic parameters between elderly and younger patients [see Clinical Pharmacology (12.3)]. Although clinical experiences have not identified differences in effectiveness and safety between the elderly (≥65 years) and younger patients, these conclusions are limited by small sample sizes for patients ≥75 years old.
Administration
2.3 Concomitant Use with Strong CYP2C8 Inhibitors Coadministration of ACTOS and gemfibrozil, a strong CYP2C8 inhibitor, increases pioglitazone exposure approximately 3-fold. Therefore, the maximum recommended dose of ACTOS is 15 mg daily when used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ].
US FDA labelDosage forms
Philippines
- Tablet: 15 mg, 30 mg, 45 mg
Registered products in the Philippines
68 products registered with the Food and Drug Administration (FDA) Philippines list Pioglitazone as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products68
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
ActazonePioglitazone (as hydrochloride) | 15 mg TabletAlu/PVC Blister pack x 10’s Box of 50’s | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Corbridge Group Phils., Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-1183-02 | Dec 16, 2028 | |
ActazonePioglitazone (as hydrochloride) | 30 mg TabletAlu/PVC Blister Pack x 10’s (Box of 50’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Corbridge Group Phils., Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-1184-02 | Dec 16, 2028 | |
ActosPioglitazone (as hydrochloride) | 15 mg TabletPP blister pack x 10 tablets in an aluminum bag | RxVAT-exempt | Bora Pharmaceutical Laboratories Inc.Taiwan | Celltrion Healthcare Philippines, Inc. | DR-XY26848 | Jul 2, 2030 | |
ActosPioglitazone (as hydrochloride) | 30 mg TabletPVC/PVDC blister pack x 10 tablets in an aluminum bag (Box of 10's and 30's) | RxVAT-exempt | Takeda Pharmaceutical Company Limited (Hikari Plant)Japan | Importer: Celltrion Healthcare Philippines, Inc. | DR-XY26847 | Jul 5, 2029 | |
Coglitazone 30Pioglitazone (as hydrochloride) | 30 mg TabletAlu/PVC Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-1184-03 | Dec 16, 2028 | |
DeculinPioglitazone (as hydrochloride) | 15mg TabletPolycellonium Strip Pack x 6's (Box of 30's) | RxVAT-exempt | PT. Dexa MedicaIndonesia | Glorious Dexa Mandaya, Inc. | DRP-11722 | Apr 22, 2027 | |
DeculinPioglitazone (as hydrochloride) | 30mg TabletPolycellonium Strip Pack x 6's (Box of 30's) | RxVAT-exempt | PT. Dexa MedicaIndonesia | Glorious Dexa Mandaya, Inc. | DRP-11721 | Apr 22, 2027 | |
Glipitone-30Pioglitazone (as hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Akums Drugs & Pharmaceuticals Ltd. (Plant I – Solid Oral Dosage Facility)India | Pharmalife DistributionImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-2748 | Jan 31, 2029 | |
GlitazPioglitazone (as hydrochloride) | 15 mg TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | HIZON LABORATORIES, INCPhilippines | Trader: THE CATHAY YSS DISTRIBUTORS CO., INC | DR-XY37130 | Dec 1, 2029 | |
GlitazPioglitazone Hydrochloride | 30 mg TabletAlu/Alu Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | The Cathay YSS Distributors Co., Inc.Importer: Ambica International Corporation | DRP-2807-02 | Feb 22, 2029 | |
Glito 15Pioglitazone (as Hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medley Pharmaceuticals LimitedIndia | Ambica International Corporation | DRP-5217 | Jul 8, 2028 | |
Glito 30Pioglitazone (as Hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Medley Pharmaceuticals LimitedIndia | Ambica International Corporation | DRP-5216 | Jul 8, 2028 | |
Goglitazone 15Pioglitazone (as hydrochloride) | 15 mg TabletAlu/PVC Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-1183-03 | Dec 16, 2028 | |
Goglitazone 30Pioglitazone (as hydrochloride) | 30 mg TabletAlu/Alu Blister pack x 14's (Box of 28's) | RxVAT-exempt | Ind-Swift LimitedIndia | Applied Pharmaceutical Distribution IncImporter: Medinova Pharmaceutical Inc. | DRP-13473-01 | Feb 27, 2028 | |
Goglitazone-15Pioglitazone (as hydrochloride) | 15mg TabletAlu/Alu Blister pack x 14's (Box of 28's) | RxVAT-exempt | Ind-Swift LimitedIndia | Applied Pharmaceutical Distribution IncImporter: Medinova Pharmaceutical Inc. | DRP-13156-01 | Dec 12, 2027 | |
InsulevitaPioglitazone (as hydrochloride) | 15 mg TabletAlu/PVC Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Vitalife Pharma & Medical Supply Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-1183-04 | Dec 16, 2028 | |
InsulevitaPioglitazone (as hydrochloride) | 30 mg TabletAlu / PVC Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Vitalife Pharma & Medical Supply Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-1184-04 | Dec 16, 2028 | |
MaedglitazonPioglitazone (as hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Akums Drugs & Pharmaceuticals Ltd. (Plant I – Solid Oral Dosage Facility)India | Maed Pharma CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-2748-01 | Jan 31, 2029 | |
NonePioglitazone (as hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation | DRP-2167-02 | May 13, 2028 | |
NonePioglitazone (as hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | ATC Healthcare International Corp.Importer: Ambica International Corporation | DRP-2167-03 | May 13, 2028 | |
NonePioglitazone (as Hydrochloride) | 30 mg TabletFlex Foil Strip x 10's (Box of 30's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | RiteMED Phils, Inc.Trader: Unilab, Inc. | DRP-10059-01 | Jun 5, 2029 | |
NonePioglitazone (as hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Akums Drugs & Pharmaceuticals Ltd. (Plant I – Solid Oral Dosage Facility)India | Maed Pharma CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-2748-02 | Jan 31, 2029 | |
NonePioglitazone Hydrochloride | 30 mg TabletAlu/Alu Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-2807-03 | Feb 22, 2029 | |
NonePioglitazone (as Hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Medley Pharmaceuticals LimitedIndia | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-5216-01 | Jul 8, 2028 | |
Pio-SourcePioglitazone (as hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Life and Health Source Pharmaceutical Distribution Co.Importer: Ambica International Corporation | DRP-2167-06 | May 13, 2028 | |
Pio-SourcePioglitazone Hydrochloride | 30 mg TabletAlu/Alu Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Life and Health Source Pharmaceutical Distribution Co.Importer: Ambica International Corporation | DRP-2807-06 | Feb 22, 2029 | |
PiodartPioglitazone Hydrochloride | 30 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-2807-01 | Feb 22, 2029 | |
PiogenPioglitazone Hydrochloride | 30 mg TabletBlister Pack x 10's (Box of 50's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DR-XY35397 | Feb 4, 2028 | |
Pioglifar 15Pioglitazone (as hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-2167-04 | May 13, 2028 | |
Pioglifar 30Pioglitazone Hydrochloride | 30 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-2807-04 | Feb 22, 2029 | |
Pioglinova - 30Pioglitazone (as hydrochloride) | 30 mg TabletAlu/Alu Blister pack x 14's (Box of 28's) | RxVAT-exempt | Ind-Swift LimitedIndia | Medinova Pharmaceutical Inc. | DRP-13473 | Feb 27, 2028 | |
Pioglinova - 45Pioglitazone (as hydrochloride) | 45 mg TabletAlu/Alu Blister pack x 14's (Box of 28's) | RxVAT-exempt | Ind-Swift LimitedIndia | Medinova Pharmaceutical Inc. | DRP-13472 | Feb 27, 2028 | |
Pioglinova-15Pioglitazone (as Hydrochloride) | 15 mg TabletAlu/Alu Blister Pack of 14's (Box of 28's) | RxVAT-exempt | Ind-Swift LimitedIndia | Medinova Pharmaceutical, Inc. | DRP-13156 | Dec 12, 2027 | |
Pioglitasaph-15Pioglitazone (As Hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-13618 | Mar 17, 2028 | |
Pioglitasaph-30Pioglitazone (As Hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-13617 | May 28, 2031 | |
Pioglizein-15Pioglitazone (as hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-2167-05 | May 13, 2028 | |
Pioglizein-30Pioglitazone Hydrochloride | 30 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Kodapharm Med Corp.Importer: Ambica International Corporation | DRP-2807-05 | Feb 22, 2029 | |
PioglonPioglitazone hydrochloride | 15 mg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Interhealthcare Pharmaceuticals, Inc. | DRP-1602 | Aug 13, 2028 | |
PioMed-30Pioglitazone (as hydrochloride) | 30 mg TabletAlu-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Flourish PharmaIndia | Biophil Medical Equipment and Supplies Trading. | DRP-16090 | Oct 30, 2029 | |
Piophil-30Pioglitazone (As Hydrochloride) | 30mg TabletsAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-18584 | Aug 4, 2031 | |
Piorance-15Pioglitazone (as hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Aristo Pharma Philippines, Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6611 | Mar 30, 2037 | |
Piorance-30Pioglitazone (as hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Aristo Pharma Philippines, Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6610 | Mar 30, 2038 | |
Piostal-15Pioglitazone (as hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-2167 | May 13, 2028 | |
Piostal-30Pioglitazone Hydrochloride | 30 mg TabletAlu/Alu Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-2807 | Feb 22, 2029 | |
PiotazPioglitazone (as hydrochloride) | 15 mg TabletAlu/PVC Blister Pack x 10’s (Box of 50’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-1183 | Dec 16, 2028 | |
PiotazPioglitazone (as hydrochloride) | 30 mg TabletAlu/PVC Blister Pack x 10’s (Box of 50’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-1184 | Dec 16, 2028 | |
PiotriphilPioglitazone (as hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ratnaris Pharmaceuticals Private LimitedIndia | AMB HK Enterprises, Inc. | DRp-18629 | Aug 26, 2031 | |
PiozonePioglitazone (as Hydrochloride) | 15 mg TabletFlex Foil x 10's (Box of 30's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: Unilab, Inc. | DRP-1713 | Nov 17, 2029 | |
PiozonePioglitazone (as Hydrochloride) | 30 mg TabletFlex Foil Strip x 10's (Box of 30's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, INC. | DRP-10059 | Jun 5, 2029 | |
Piozulin 15Pioglitazone (as Hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 15’s (Box of 30’s) | RxVAT-exempt | Cadila Pharmaceuticals LimitedIndia | Ambica International Corporation | DRP-5654 | Nov 12, 2031 | |
Piozulin 30Pioglitazone (as Hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Cadila Pharmaceuticals LimitedIndia | Ambica International Corporation | DRP-5648 | Sep 16, 2030 | |
PoglavitPioglitazone (as Hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medley Pharmaceuticals LimitedIndia | Bewell Nutraceuticals Corp.Importer: Ambica International Corporation | DRP-5217-01 | Jul 8, 2028 | |
PoglavitPioglitazone (as Hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Medley Pharmaceuticals LimitedIndia | Bewell Nutraceuticals Corp.Importer: Ambica International Corporation | DRP-5216-03 | Jul 8, 2028 | |
PparPioglitazone (as Hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Medley Pharmaceuticals LimitedIndia | Bell-Kenz Pharma Inc.Importer: Ambica International Corporation | DRP-5216-02 | Jul 8, 2028 | |
PrialtaPioglitazone (as hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Micro Labs LimitedIndia | Zuellig Pharma CorporationImporter: OEP Philippines, Inc. | DRP-12873 | May 7, 2029 | |
PrialtaPioglitazone (as hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Micro Labs LimitedIndia | Zuellig Pharma CorporationImporter: OEP Philippines, Inc. | DRP-12876 | May 7, 2029 | |
PrialtaPioglitazone (as hydrochloride) | 45 mg TabletAlu/Alu Blister Pack x 10s (Box of 50s) | RxVAT-exempt | Micro Labs LimitedIndia | Zuellig Pharma CorporationImporter: OEP Philippines, Inc. | DRP-12875 | Mar 12, 2031 | |
RetaglitzPioglitazone (as hydrochloride) | 15 mg TabletAlu/Alu Blister Pack of 14's (Box of 28's; Box of 98's) | RxVAT-exempt | Ind-Swift LimitedIndia | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-13156-02 | Dec 12, 2027 | |
RetaglitzPioglitazone (as hydrochloride) | 30 mg TabletAlu/Alu Blister Pack of 14's (Box of 28's; Box of 98's) | RxVAT-exempt | Ind-Swift LimitedIndia | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-13473-02 | Feb 27, 2028 | |
Saphlitees-Ge15Pioglitazone (as hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-17946 | Apr 14, 2031 | |
Saphlitees-Ge30Pioglitazone (as hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-17945 | Apr 14, 2031 | |
UnbrandedPioglitazone (as Hydrochloride) | 15 mg TabletFlex Foil x 10's (Box of 30's) | RxVAT-exempt | Amherst Laboratories, Inc.Laguna | RiteMED Phils, Inc.Trader: Unilab, Inc. | DRP-1713-01 | Nov 17, 2029 | |
ZealPioglitazone (as hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 7's (Box of 14's and 28's) | RxVAT-exempt | Maple Pharmaceuticals Pvt. Ltd.Pakistan | Ambica International Corporation | DRP-5746 | Jan 3, 2028 | |
ZealPioglitazone (as hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 7's (Box of 14's and 28's) | RxVAT-exempt | Maple Pharmaceuticals Pvt. Ltd.Pakistan | Ambica International Corporation | DRP-5747 | Jan 3, 2028 | |
ZiatonPioglitazone (as hydrochloride) | 15mg TABLETAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Despina Pharma Inc. | DRP-14248 | Aug 2, 2028 | |
ZiatonPioglitazone (as hydrochloride) | 30mg TabletStore at temperatures not exceeding 30°C. Protect from light | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Despina Pharma Inc. | DRP-14249 | Aug 2, 2028 | |
ZolidPioglitazone (as hydrochloride) | 15 mg TabletAlu/Alu Blister Pack x 7's (Box of 14's) | RxVAT-exempt | Getz Pharma (Pvt.), Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY33842 | May 29, 2030 | |
ZolidPioglitazone (as hydrochloride) | 30 mg TabletAlu/Alu Blister Pack x 7's (Box of 14’s) | RxVAT-exempt | GETZ PHARMA (PVT.), LTD.Pakistan | Importer: GETZ PHARMA (PHILS.), INC. | DR-XY33381 | May 28, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Round tablet contains pioglitazone as follows: • 15 mg: White to off-white, debossed with "ACTOS" on one side and "15" on the other • 30 mg: White to off-white, debossed with "ACTOS" on one side and "30" on the other • 45 mg: White to off-white, debossed with "ACTOS" on one side and "45" on the other Tablets: 15 mg, 30 mg, and 45 mg (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- • Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure. Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk. Monitor patients for signs and symptoms. (5.1)
- • Hypoglycemia: When used with insulin or an insulin secretagogue, a lower dose of the insulin or insulin secretagogue may be needed to reduce the risk of hypoglycemia. (5.2)
- • Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality cannot be excluded. If liver injury is detected, promptly interrupt ACTOS and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart ACTOS if liver injury is confirmed and no alternate etiology can be found. (5.3)
- • Bladder cancer: May increase the risk of bladder cancer. Do not use in patients with active bladder cancer. Use caution when using in patients with a prior history of bladder cancer. (5.4)
- • Edema: Dose-related edema may occur. (5.5)
- • Fractures: Increased incidence in female patients. Apply current standards of care for assessing and maintaining bone health. (5.6)
- • Macular edema: Postmarketing reports. Recommend regular eye exams in all patients with diabetes according to current standards of care with prompt evaluation for acute visual changes. (5.7)
- • Macrovascular outcomes: …
5.1 Congestive Heart Failure
5.1 Congestive Heart Failure ACTOS, like other thiazolidinediones, can cause dose-related fluid retention when used alone or in combination with other antidiabetic medications and is most common when ACTOS is used in combination with insulin. Fluid retention may lead to or exacerbate congestive heart failure. Patients should be observed for signs and symptoms of congestive heart failure.
If congestive heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of ACTOS must be considered [see Boxed Warning, Contraindications (4), and Adverse Reactions (6.1)].
5.2 Hypoglycemia
5.2 Hypoglycemia Patients receiving ACTOS in combination with insulin or other antidiabetic medications (particularly insulin secretagogues such as sulfonylureas) may be at risk for hypoglycemia. A reduction in the dose of the concomitant antidiabetic medication may be necessary to reduce the risk of hypoglycemia [see Dosage and Administration (2.2)].
5.3 Hepatic Effects
5.3 Hepatic Effects There have been postmarketing reports of fatal and non-fatal hepatic failure in patients taking ACTOS, although the reports contain insufficient information necessary to establish the probable cause. There has been no evidence of drug-induced hepatotoxicity in the ACTOS controlled clinical trial database to date [see Adverse Reactions (6.1)].
Patients with type 2 diabetes may have fatty liver disease or cardiac disease with episodic congestive heart failure, both of which may cause liver test abnormalities, and they may also have other forms of liver disease, many of which can be treated or managed. Therefore, obtaining a liver test panel (serum alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, and total bilirubin) and assessing the patient is recommended before initiating ACTOS therapy.
In patients with abnormal liver tests, ACTOS should be initiated with caution. Measure liver tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. In this clinical context, if the patient is found to have abnormal liver tests (ALT greater than 3 times the upper limit of the reference range), ACTOS treatment should be interrupted and investigation done to establish the probable cause.
ACTOS should not be restarted in these patients without another explanation for the liver test abnormalities. Patients who have serum ALT greater than three times the reference range with serum total bilirubin greater than two times the reference range without alternative etiologies are at risk for severe drug-induced liver injury, and should not be restarted on ACTOS.
For patients with lesser elevations of serum ALT or bilirubin and with an alternate probable cause, treatment with ACTOS can be used with caution.
5.4 Urinary Bladder Tumors
5.4 Urinary Bladder Tumors Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study [see Nonclinical Toxicology (13.1)]. In addition, during the three year PROactive clinical trial, 14 patients out of 2605 (0.54%) randomized to ACTOS and 5 out of 2633 (0.19%) randomized to placebo were diagnosed with bladder cancer.
After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 6 (0.23%) cases on ACTOS and two (0.08%) cases on placebo. After completion of the trial, a large subset of patients was observed for up to 10 additional years, with little additional exposure to ACTOS.
During the 13 years of both PROactive and observational follow-up, the occurrence of bladder cancer did not differ between patients randomized to ACTOS or placebo (HR =1.00; [95% CI: 0.59−1.72]). Findings regarding the risk of bladder cancer in patients exposed to ACTOS vary among observational studies; some did not find an increased risk of bladder cancer associated with ACTOS, while others did.
A large prospective10-year observational cohort study conducted in the United States found no statistically significant increase in the risk of bladder cancer in diabetic patients ever exposed to ACTOS, compared to those never exposed to ACTOS (HR =1.06 [95% CI 0.89−1.26]). A retrospective cohort study conducted with data from the United Kingdom found a statistically significant association between ever exposure to ACTOS and bladder cancer (HR: 1.63; [95% CI: 1.22−2.19]).
Associations between cumulative dose or cumulative duration of exposure to ACTOS and bladder cancer were not detected in some studies including the 10-year observational study in the U.S., but were in others. Inconsistent findings and limitations inherent in these and other studies preclude conclusive interpretations of the observational data.
ACTOS may be associated with an increase in the risk of urinary bladder tumors. There are insufficient data to determine whether pioglitazone is a tumor promoter for urinary bladder tumors. Consequently, ACTOS should not be used in patients with active bladder cancer and the benefits of glycemic control versus unknown risks for cancer recurrence with ACTOS should be considered in patients with a prior history of bladder cancer.
5.5 Edema
5.5 Edema In controlled clinical trials, edema was reported more frequently in patients treated with ACTOS than in placebo-treated patients and is dose-related [see Adverse Reactions (6.1)]. In postmarketing experience, reports of new onset or worsening edema have been received. ACTOS should be used with caution in patients with edema.
Because thiazolidinediones, including ACTOS, can cause fluid retention, which can exacerbate or lead to congestive heart failure, ACTOS should be used with caution in patients at risk for congestive heart failure. Patients treated with ACTOS should be monitored for signs and symptoms of congestive heart failure [see Boxed Warning, Warnings and Precautions (5.1) and Patient Counseling Information (17)].
5.6 Fractures In PROactive
5.6 Fractures In PROactive (the Prospective Pioglitazone Clinical Trial in Macrovascular Events), 5238 patients with type 2 diabetes and a history of macrovascular disease were randomized to ACTOS (N=2605), force-titrated up to 45 mg daily or placebo (N=2633) in addition to standard of care. During a mean follow-up of 34.5 months, the incidence of bone fracture in females was 5.1% (44/870) for ACTOS versus 2.5% (23/905) for placebo.
This difference was noted after the first year of treatment and persisted during the course of the study. The majority of fractures observed in female patients were nonvertebral fractures including lower limb and distal upper limb. No increase in the incidence of fracture was observed in men treated with ACTOS (1.7%) versus placebo (2.1%).
The risk of fracture should be considered in the care of patients, especially female patients, treated with ACTOS and attention should be given to assessing and maintaining bone health according to current standards of care.
5.7 Macular Edema
5.7 Macular Edema Macular edema has been reported in postmarketing experience in diabetic patients who were taking ACTOS or another thiazolidinedione. Some patients presented with blurred vision or decreased visual acuity, but others were diagnosed on routine ophthalmologic examination. Most patients had peripheral edema at the time macular edema was diagnosed.
Some patients had improvement in their macular edema after discontinuation of the thiazolidinedione. Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care. Patients with diabetes who report any visual symptoms should be promptly referred to an ophthalmologist, regardless of the patient's underlying medications or other physical findings [see Adverse Reactions (6.1)].
5.8 Macrovascular Outcomes
5.8 Macrovascular Outcomes There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ACTOS.
Drug interactions
- • Strong CYP2C8 inhibitors (e.g., gemfibrozil) increase pioglitazone concentrations. Limit ACTOS dose to 15 mg daily. (2.3, 7.1)
- • CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations. (7.2)
- • Topiramate may decrease pioglitazone concentrations. (7.3)
7.1 Strong CYP2C8 Inhibitors
7.1 Strong CYP2C8 Inhibitors An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the serum concentration-time curve or AUC) and half-life (t 1/2) of pioglitazone. Therefore, the maximum recommended dose of ACTOS is 15 mg daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].
7.2 CYP2C8 Inducers
7.2 CYP2C8 Inducers An inducer of CYP2C8 (e.g., rifampin) may significantly decrease the exposure (AUC) of pioglitazone. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOS, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dose of 45 mg for ACTOS [see Clinical Pharmacology (12.3)].
7.3 Topiramate
7.3 Topiramate A decrease in the exposure of pioglitazone and its active metabolites were noted with concomitant administration of pioglitazone and topiramate [see Clinical Pharmacology (12.3)]. The clinical relevance of this decrease is unknown; however, when ACTOS and topiramate are used concomitantly, monitor patients for adequate glycemic control.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
In vitro data demonstrate that multiple CYP isoforms are involved in the metabolism of pioglitazone, which include CYP2C8 and, to a lesser degree, CYP3A4 with additional contributions from a variety of other isoforms including the mainly extrahepatic CYP1A1.
In vivo study of pioglitazone in combination with gemfibrozil, a strong CYP2C8 inhibitor, showed that pioglitazone is a CYP2C8 substrate [see Dosage and Administration (2.3) and Drug Interactions (7) ] .
Urinary 6ß-hydroxycortisol/cortisol ratios measured in patients treated with ACTOS showed that pioglitazone is not a strong CYP3A4 enzyme inducer.
7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil) increase pioglitazone concentrations.
( 2.3 , 7.1 ) • CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations.
( 7.3 ) 7.1 Strong CYP2C8 Inhibitors An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the serum concentration-time curve or AUC) and half-life (t 1/2 ) of pioglitazone.
Therefore, the maximum recommended dose of ACTOS is 15 mg daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ]. 7.2 CYP2C8 Inducers An inducer of CYP2C8 (e.g., rifampin) may significantly decrease the exposure (AUC) of pioglitazone.
Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOS, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dose of 45 mg for ACTOS [see Clinical Pharmacology (12.3) ] . 7.3 Topiramate A decrease in the exposure of pioglitazone and its active metabolites were noted with concomitant administration of pioglitazone and topiramate [see Clinical Pharmacology (12.3) ] .
Adverse reactions
- The following serious adverse reactions are discussed elsewhere in the labeling: • Congestive heart failure [see Boxed Warning and Warnings and Precautions (5.1)] • Edema [see Warnings and Precautions (5.5)] • Fractures [see Warnings and Precautions (5.6)] Most common adverse reactions (≥5%) are upper respiratory tract infection, headache, sinusitis, myalgia, and pharyngitis. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals America, Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Over 8500 patients with type 2 diabetes have been treated with ACTOS in randomized, double-blind, controlled clinical trials, including 2605 patients with type 2 diabetes and macrovascular disease treated with ACTOS in the PROactive clinical trial.
In these trials, over 6000 patients have been treated with ACTOS for six months or longer, over 4500 patients have been treated with ACTOS for one year or longer, and over 3000 patients have been treated with ACTOS for at least two years. In six pooled 16- to 26-week placebo-controlled monotherapy and 16- to 24-week add-on combination therapy trials, the incidence of withdrawals due to adverse events was 4.5% for patients treated with ACTOS and 5.8% for comparator-treated patients.
The most common adverse events leading to withdrawal were related to inadequate glycemic control, although the incidence of these events was lower (1.5%) with ACTOS than with placebo (3.0%). In the PROactive trial, the incidence of withdrawals due to adverse events was 9.0% for patients treated with ACTOS and 7.7% for placebo-treated patients.
Congestive heart failure was the most common serious adverse event leading to withdrawal occurring in 1.3% of patients treated with ACTOS and 0.6% of patients treated with placebo. Common Adverse Events: 16- to 26-Week Monotherapy Trials A summary of the incidence and type of common adverse events reported in three pooled 16- to 26-week placebo-controlled monotherapy trials of ACTOS is provided in Table 1.
Terms that are reported represent those that occurred at an incidence of >5% and more commonly in patients treated with ACTOS than in patients who received placebo. None of these adverse events were related to ACTOS dose. Table 1. Three Pooled 16- to 26-Week Placebo-Controlled Clinical Trials of ACTOS Monotherapy: Adverse Events Reported at an Incidence >5% and More Commonly in Patients Treated with ACTOS than in Patients Treated with Placebo % of Patients Placebo N=259 ACTOS N=606 Upper Respiratory Tract Infection 8.5 13.2 Headache 6.9 9.1 Sinusitis 4.6
6.3 Myalgia 2
6.3 Myalgia 2.7 5.4 Pharyngitis 0.8 5.1 Common Adverse Events: 16- to 24-Week Add-on Combination Therapy Trials A summary of the overall incidence and types of common adverse events reported in trials of ACTOS add-on to sulfonylurea is provided in Table 2. Terms that are reported represent those that occurred at an incidence of >5% and more commonly with the highest tested dose of ACTOS.
Table 2. 16- to 24-Week Clinical Trials of ACTOS Add-on to Sulfonylurea 16-Week Placebo-Controlled Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 30 mg + Sulfonylurea than in Patients Treated with Placebo + Sulfonylurea % of Patients Placebo + Sulfonylurea N=187 ACTOS 15 mg + Sulfonylurea N=184 ACTOS 30 mg + Sulfonylurea N=189 Edema 2.1 1.6 12.7 Headache 3.7 4.3 5.3 Flatulence 0.5 2.7
6.3 Weight Increased 0 2
6.3 Weight Increased 0 2.7 5.3 24-Week Non-Controlled Double-Blind Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 45 mg + Sulfonylurea than in Patients Treated with ACTOS 30 mg + Sulfonylurea % of Patients ACTOS 30 mg + Sulfonylurea N=351 ACTOS 45 mg + Sulfonylurea N=351 Hypoglycemia 13.4 15.7 Edema 10.5 23.1 Upper Respiratory Tract Infection 12.3 14.8 Weight Increased 9.1 13.4 Urinary Tract Infection 5.7
6.8 Note
6.8 Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of "edema." A summary of the overall incidence and types of common adverse events reported in trials of ACTOS add-on to metformin is provided in Table 3. Terms that are reported represent those that occurred at an incidence of >5% and more commonly with the highest tested dose of ACTOS.
Table 3. 16- to 24-Week Clinical Trials of ACTOS Add-on to Metformin 16-Week Placebo-Controlled Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS + Metformin than in Patients Treated with Placebo + Metformin % of Patients Placebo + Metformin N=160 ACTOS 30 mg + Metformin N=168 Edema 2.5
6.0 Headache 1
6.0 Headache 1.9 6.0 24-Week Non-Controlled Double-Blind Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 45 mg + Metformin than in Patients Treated with ACTOS 30 mg + Metformin % of Patients ACTOS 30 mg + Metformin N=411 ACTOS 45 mg + Metformin N=416 Upper Respiratory Tract Infection 12.4 13.5 Edema 5.8 13.9 Headache 5.4 5.8 Weight Increased 2.9
6.7 Note
6.7 Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of "edema." Table 4 summarizes the incidence and types of common adverse events reported in trials of ACTOS add-on to insulin. Terms that are reported represent those that occurred at an incidence of >5% and more commonly with the highest tested dose of ACTOS.
Table 4. 16- to 24-Week Clinical Trials of ACTOS Add-on to Insulin 16-Week Placebo-Controlled Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 30 mg + Insulin than in Patients Treated with Placebo + Insulin % of Patients Placebo + Insulin N=187 ACTOS 15 mg + Insulin N=191 ACTOS 30 mg + Insulin N=188 Hypoglycemia 4.8 7.9 15.4 Edema 7.0 12.6 17.6 Upper Respiratory Tract Infection 9.6 8.4 14.9 Headache 3.2 3.1
6.9 Weight Increased 0
6.9 Weight Increased 0.5 5.2
6.4 Back Pain 4
6.4 Back Pain 4.3 2.1 5.3 Dizziness 3.7 2.6 5.3 Flatulence 1.6 3.7 5.3 24-Week Non-Controlled Double-Blind Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 45 mg + Insulin than in Patients Treated with ACTOS 30 mg + Insulin % of Patients ACTOS 30 mg + Insulin N=345 ACTOS 45 mg + Insulin N=345 Hypoglycemia 43.5 47.8 Edema 22.0 26.1 Weight Increased 7.2 13.9 Urinary Tract Infection 4.9 8.7 Diarrhea 5.5 5.8 Back Pain 3.8
6.4 Blood Creatine Phosphokinase Increased 4
6.4 Blood Creatine Phosphokinase Increased 4.6 5.5 Sinusitis 4.6 5.5 Hypertension 4.1 5.5 Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of "edema." A summary of the overall incidence and types of common adverse events reported in the PROactive trial is provided in Table 5. Terms that are reported represent those that occurred at an incidence of >5% and more commonly in patients treated with ACTOS than in patients who received placebo.
Table 5. PROactive Trial: Incidence and Types of Adverse Events Reported in >5% of Patients Treated with ACTOS and More Commonly than Placebo % of Patients Placebo N=2633 ACTOS N=2605 Hypoglycemia 18.8 27.3 Edema 15.3 26.7 Cardiac Failure 6.1 8.1 Pain in Extremity 5.7
6.4 Back Pain 5
6.4 Back Pain 5.1 5.5 Chest Pain 5.0 5.1 Mean duration of patient follow-up was 34.5 months. Congestive Heart Failure A summary of the incidence of adverse events related to congestive heart failure is provided in Table 6 for the 16- to 24-week add-on to sulfonylurea trials, for the 16- to 24-week add-on to insulin trials, and for the 16- to 24-week add-on to metformin trials.
None of the events were fatal. Table 6. Treatment-Emergent Adverse Events of Congestive Heart Failure (CHF) Patients Treated with ACTOS or Placebo Added on to a Sulfonylurea Number (%) of Patients Placebo-Controlled Trial (16 weeks) Non-Controlled Double-Blind Trial (24 weeks) Placebo + Sulfonylurea N=187 ACTOS 15 mg + Sulfonylurea N=184 ACTOS 30 mg + Sulfonylurea N=189 ACTOS 30 mg + Sulfonylurea N=351 ACTOS 45 mg + Sulfonylurea N=351 At least one congestive heart failure event 2 (1.1%) 0 0 1 (0.3%) 6 (1.7%) Hospitalized 2 (1.1%) 0 0 0 2 (0.6%) Patients Treated with ACTOS or Placebo Added on to Insulin Number (%) of Patients Placebo-Controlled Trial (16 weeks) Non-Controlled Double-Blind Trial (24 weeks) Placebo + Insulin N=187 ACTOS 15 mg + Insulin N=191 ACTOS 30 mg + Insulin N=188 ACTOS 30 mg + Insulin N=345 ACTOS 45 mg + Insulin N=345 At least one congestive heart failure event 0 2 (1.0%) 2 (1.1%) 3 (0.9%) 5 (1.4%) Hospitalized 0 2 (1.0%) 1 (0.5%) 1 (0.3%) 3 (0.9%) Patients Treated with ACTOS or Placebo Added on to Metformin Number (%) of Patients Placebo-Controlled Trial (16 weeks) Non-Controlled Double-Blind Trial (24 weeks) Placebo + Metformin N=160 ACTOS 30 mg + Metformin N=168 ACTOS 30 mg + Metformin N=411 ACTOS 45 mg + Metformin N=416 At least one congestive heart failure event 0 1 (0.6%) 0 1 (0.2%) Hospitalized 0 1 (0.6%) 0 1 (0.2%) Patients with type 2 diabetes and NYHA class II or early class III congestive heart failure were randomized to receive 24 weeks of double-blind treatment with either ACTOS at daily doses of 30 mg to 45 mg (n=262) or glyburide at daily doses of 10 mg to 15 mg (n=256).
A summary of the incidence of adverse events related to congestive heart failure reported in this study is provided in Table 7. Table 7. Treatment-Emergent Adverse Events of Congestive Heart Failure (CHF) in Patients with NYHA Class II or III Congestive Heart Failure Treated with ACTOS or Glyburide Number (%) of Subjects ACTOS N=262 Glyburide N=256 Death due to cardiovascular causes (adjudicated) 5 (1.9%) 6 (2.3%) Overnight hospitalization for worsening CHF (adjudicated) 26 (9.9%) 12 (4.7%) Emergency room visit for CHF (adjudicated) 4 (1.5%) 3 (1.2%) Patients experiencing CHF progression during study 35 (13.4%) 21 (8.2%) Congestive heart failure events leading to hospitalization that occurred during the PROactive trial are summarized in Table 8.
Table 8. Treatment-Emergent Adverse Events of Congestive Heart Failure (CHF) in PROactive Trial Number (%) of Patients Placebo N=2633 ACTOS N=2605 At least one hospitalized congestive heart failure event 108 (4.1%) 149 (5.7%) Fatal 22 (0.8%) 25 (1.0%) Hospitalized, nonfatal 86 (3.3%) 124 (4.7%) Cardiovascular Safety In the PROactive trial, 5238 patients with type 2 diabetes and a history of macrovascular disease were randomized to ACTOS (N=2605), force-titrated up to 45 mg daily or placebo (N=2633) in addition to standard of care.
Almost all patients (95%) were receiving cardiovascular medications (beta blockers, ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers, nitrates, diuretics, aspirin, statins and fibrates). At baseline, patients had a mean age of 62 years, mean duration of diabetes of 9.5 years, and mean HbA1c of 8.1%.
Mean duration of follow-up was 34.5 months. The primary objective of this trial was to examine the effect of ACTOS on mortality and macrovascular morbidity in patients with type 2 diabetes mellitus who were at high risk for macrovascular events. The primary efficacy variable was the time to the first occurrence of any event in a cardiovascular composite endpoint that included all-cause mortality, nonfatal myocardial infarction (MI) including silent MI, stroke, acute coronary syndrome, cardiac intervention including coronary artery bypass grafting or percutaneous intervention, major leg amputation above the ankle, and bypass surgery or revascularization in the leg.
A total of 514 (19.7%) patients treated with ACTOS and 572 (21.7%) placebo-treated patients experienced at least one event from the primary composite endpoint (hazard ratio 0.90; 95% Confidence Interval: 0.80, 1.02; p=0.10). Although there was no statistically significant difference between ACTOS and placebo for the three-year incidence of a first event within this composite, there was no increase in mortality or in total macrovascular events with ACTOS.
The number of first occurrences and total individual events contributing to the primary composite endpoint is shown in Table 9. Table 9. PROactive: Number of First and Total Events for Each Component within the Cardiovascular Composite Endpoint Cardiovascular Events Placebo N=2633 ACTOS N=2605 First Events n (%) Total events n First Events n (%) Total events n Any event 572 (21.7) 900 514 (19.7) 803 All-cause mortality 122 (4.6) 186 110 (4.2) 177 Nonfatal myocardial infarction (MI) 118 (4.5) 157 105 (4.0) 131 Stroke 96 (3.6) 119 76 (2.9) 92 Acute coronary syndrome 63 (2.4) 78 42 (1.6) 65 Cardiac intervention (CABG/PCI) 101 (3.8) 240 101 (3.9) 195 Major leg amputation 15 (0.6) 28 9 (0.3) 28 Leg revascularization 57 (2.2) 92 71 (2.7) 115 CABG = coronary artery bypass grafting; PCI = percutaneous intervention Weight Gain Dose-related weight gain occurs when ACTOS is used alone or in combination with other antidiabetic medications.
The mechanism of weight gain is unclear but probably involves a combination of fluid retention and fat accumulation. Tables 10 and 11 summarize the changes in body weight with ACTOS and placebo in the 16- to 26-week randomized, double-blind monotherapy and 16- to 24-week combination add-on therapy trials and in the PROactive trial.
Table 10. Weight Changes (kg) from Baseline During Randomized, Double-Blind Clinical Trials Control Group (Placebo) ACTOS 15 mg ACTOS 30 mg ACTOS 45 mg Median (25 th /75 th percentile) Median (25 th /75 th percentile) Median (25 th /75 th percentile) Median (25 th /75 th percentile) Monotherapy (16 to 26 weeks) -1.4 (-2.7/0.0) N=256 0.9 (-0.5/3.4) N=79 1.0 (-0.9/3.4) N=188 2.6 (0.2/5.4) N=79 Combination Therapy (16 to 24 weeks) Sulfonylurea -0.5 (-1.8/0.7) N=187 2.0 (0.2/3.2) N=183 3.1 (1.1/5.4) N=528 4.1 (1.8/7.3) N=333 Metformin -1.4 (-3.2/0.3) N=160 N/A 0.9 (-1.3/3.2) N=567 1.8 (-0.9/5.0) N=407 Insulin 0.2 (-1.4/1.4) N=182 2.3 (0.5/4.3) N=190 3.3 (0.9/6.3) N=522 4.1 (1.4/6.8) N=338 Table 11.
Median Change in Body Weight in Patients Treated with ACTOS Versus Patients Treated with Placebo During the Double-Blind Treatment Period in the PROactive Trial Placebo ACTOS Median (25 th /75 th percentile) Median (25 th /75 th percentile) Change from baseline to final visit (kg) -0.5 (-3.3, 2.0) N=2581 +3.6 (0.0, 7.5) N=2560 Note: Median exposure for both ACTOS and Placebo was 2.7 years. Edema Edema induced from taking ACTOS is reversible when ACTOS is discontinued.
The edema usually does not require hospitalization unless there is coexisting congestive heart failure. A summary of the frequency and types of edema adverse events occurring in clinical investigations of ACTOS is provided in Table 12. Table 12. Adverse Events of Edema in Patients Treated with ACTOS Number (%) of Patients Placebo ACTOS 15 mg ACTOS 30 mg ACTOS 45 mg Monotherapy (16 to 26 weeks) 3 (1.2%) N=259 2 (2.5%) N= 81 13 (4.7%) N= 275 11 (6.5%) N=169 Combined Therapy (16 to 24 weeks) Sulfonylurea 4 (2.1%) N=187 3 (1.6%) N=184 61 (11.3%) N=540 81 (23.1%) N=351 Metformin 4 (2.5%) N=160 N/A 34 (5.9%) N=579 58 (13.9%) N=416 Insulin 13 (7.0%) N=187 24 (12.6%) N=191 109 (20.5%) N=533 90 (26.1%) N=345 Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of "edema." Table 13.
Adverse Events of Edema in Patients in the PROactive Trial Number (%) of Patients Placebo N=2633 ACTOS N=2605 419 (15.9%) 712 (27.3%) Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of "edema." Hepatic Effects There has been no evidence of induced hepatotoxicity with ACTOS in the ACTOS controlled clinical trial database to date. One randomized, double-blind 3-year trial comparing ACTOS to glyburide as add-on to metformin and insulin therapy was specifically designed to evaluate the incidence of serum ALT elevation to greater than three times the upper limit of the reference range, measured every eight weeks for the first 48 weeks of the trial then every 12 weeks thereafter.
A total of 3/1051 (0.3%) patients treated with ACTOS and 9/1046 (0.9%) patients treated with glyburide developed ALT values greater than three times the upper limit of the reference range. None of the patients treated with ACTOS in the ACTOS controlled clinical trial database to date have had a serum ALT greater than three times the upper limit of the reference range and a corresponding total bilirubin greater than two times the upper limit of the reference range, a combination predictive of the potential for severe drug-induced liver injury.
Hypoglycemia In the ACTOS clinical trials, adverse events of hypoglycemia were reported based on clinical judgment of the investigators and did not require confirmation with fingerstick glucose testing. In the 16-week add-on to sulfonylurea trial, the incidence of reported hypoglycemia was 3.7% with ACTOS 30 mg and 0.5% with placebo.
In the 16-week add-on to insulin trial, the incidence of reported hypoglycemia was 7.9% with ACTOS 15 mg, 15.4% with ACTOS 30 mg, and 4.8% with placebo. The incidence of reported hypoglycemia was higher with ACTOS 45 mg compared to ACTOS 30 mg in both the 24-week add-on to sulfonylurea trial (15.7% vs. 13.4%) and in the 24-week add-on to insulin trial (47.8% vs. 43.5%).
Three patients in these four trials were hospitalized due to hypoglycemia. All three patients were receiving ACTOS 30 mg (0.9%) in the 24-week add-on to insulin trial. An additional 14 patients reported severe hypoglycemia (defined as causing considerable interference with patient's usual activities) that did not require hospitalization.
These patients were receiving ACTOS 45 mg in combination with sulfonylurea (n=2) or ACTOS 30 mg or 45 mg in combination with insulin (n=12). Urinary Bladder Tumors Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study [see Nonclinical Toxicology (13.1)]. During the three year PROactive clinical trial, 14 patients out of 2605 (0.54%) randomized to ACTOS and 5 out of 2633 (0.19%) randomized to placebo were diagnosed with bladder cancer.
After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 6 (0.23%) cases on ACTOS and two (0.08%) cases on placebo. After completion of the trial, a large subset of patients was observed for up to 10 additional years, with little additional exposure to ACTOS.
During the 13 years of both PROactive and observational follow-up, the occurrence of bladder cancer did not differ between patients randomized to ACTOS or placebo (HR =1.00; 95% CI: 0.59-1.72) [see Warnings and Precautions (5.4)]. Laboratory Abnormalities Hematologic Effects ACTOS may cause decreases in hemoglobin and hematocrit.
In placebo-controlled monotherapy trials, mean hemoglobin values declined by 2% to 4% in patients treated with ACTOS compared with a mean change in hemoglobin of -1% to +1% in placebo-treated patients. These changes primarily occurred within the first 4 to 12 weeks of therapy and remained relatively constant thereafter.
These changes may be related to increased plasma volume associated with ACTOS therapy and are not likely to be associated with any clinically significant hematologic effects. Creatine Phosphokinase During protocol-specified measurement of serum creatine phosphokinase (CPK) in ACTOS clinical trials, an isolated elevation in CPK to greater than 10 times the upper limit of the reference range was noted in nine (0.2%) patients treated with ACTOS (values of 2150 to 11400 IU/L) and in no comparator-treated patients.
Six of these nine patients continued to receive ACTOS, two patients were noted to have the CPK elevation on the last day of dosing and one patient discontinued ACTOS due to the elevation. These elevations resolved without any apparent clinical sequelae. The relationship of these events to ACTOS therapy is unknown.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ACTOS. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- New onset or worsening diabetic macular edema with decreased visual acuity [see Warnings and Precautions (5.7)].
- Fatal and nonfatal hepatic failure [see Warnings and Precautions (5.3)]. Postmarketing reports of congestive heart failure have been reported in patients treated with ACTOS, both with and without previously known heart disease and both with and without concomitant insulin administration. In postmarketing experience, there have been reports of unusually rapid increases in weight and increases in excess of that generally observed in clinical trials. Patients who experience such increases should be assessed for fluid accumulation and volume-related events such as excessive edema and congestive heart failure [see Boxed Warning and Warnings and Precautions (5.1)].
Adverse reaction frequency tables (US label) US FDA label
| Table 1. Three Pooled 16- to 26-Week Placebo-Controlled Clinical Trials of ACTOS Monotherapy: Adverse Events Reported at an Incidence >5% and More Commonly in Patients Treated with ACTOS than in Patients Treated with Placebo | ||
|---|---|---|
| % of Patients | ||
| Placebo N=259 | ACTOS N=606 | |
| Upper Respiratory Tract Infection | 8.5 | 13.2 |
| Headache | 6.9 | 9.1 |
| Sinusitis | 4.6 | 6.3 |
| Myalgia | 2.7 | 5.4 |
| Pharyngitis | 0.8 | 5.1 |
| Table 2. 16- to 24-Week Clinical Trials of ACTOS Add-on to Sulfonylurea | |||
| 16-Week Placebo-Controlled Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 30 mg + Sulfonylurea than in Patients Treated with Placebo + Sulfonylurea | |||
| % of Patients | |||
| Placebo + Sulfonylurea N=187 | ACTOS 15 mg + Sulfonylurea N=184 | ACTOS 30 mg + Sulfonylurea N=189 | |
| Edema | 2.1 | 1.6 | 12.7 |
| Headache | 3.7 | 4.3 | 5.3 |
| Flatulence | 0.5 | 2.7 | 6.3 |
| Weight Increased | 0 | 2.7 | 5.3 |
| 24-Week Non-Controlled Double-Blind Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 45 mg + Sulfonylurea than in Patients Treated with ACTOS 30 mg + Sulfonylurea | |||
| % of Patients | |||
| ACTOS 30 mg + Sulfonylurea N=351 | ACTOS 45 mg + Sulfonylurea N=351 | ||
| Hypoglycemia | 13.4 | 15.7 | |
| Edema | 10.5 | 23.1 | |
| Upper Respiratory Tract Infection | 12.3 | 14.8 | |
| Weight Increased | 9.1 | 13.4 | |
| Urinary Tract Infection | 5.7 | 6.8 | |
| Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of "edema." | |||
| Table 3. 16- to 24-Week Clinical Trials of ACTOS Add-on to Metformin | ||
|---|---|---|
| 16-Week Placebo-Controlled Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS + Metformin than in Patients Treated with Placebo + Metformin | ||
| % of Patients | ||
| Placebo + Metformin N=160 | ACTOS 30 mg + Metformin N=168 | |
| Edema | 2.5 | 6.0 |
| Headache | 1.9 | 6.0 |
| 24-Week Non-Controlled Double-Blind TrialAdverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 45 mg + Metformin than in Patients Treated with ACTOS 30 mg + Metformin | ||
| % of Patients | ||
| ACTOS 30 mg + Metformin N=411 | ACTOS 45 mg + Metformin N=416 | |
| Upper Respiratory Tract Infection | 12.4 | 13.5 |
| Edema | 5.8 | 13.9 |
| Headache | 5.4 | 5.8 |
| Weight Increased | 2.9 | 6.7 |
| Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of "edema." | ||
| Table 4. 16- to 24-Week Clinical Trials of ACTOS Add-on to Insulin | |||
| 16-Week Placebo-Controlled Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 30 mg + Insulin than in Patients Treated with Placebo + Insulin | |||
| % of Patients | |||
| Placebo + Insulin N=187 | ACTOS 15 mg + Insulin N=191 | ACTOS 30 mg + Insulin N=188 | |
| Hypoglycemia | 4.8 | 7.9 | 15.4 |
| Edema | 7.0 | 12.6 | 17.6 |
| Upper Respiratory Tract Infection | 9.6 | 8.4 | 14.9 |
| Headache | 3.2 | 3.1 | 6.9 |
| Weight Increased | 0.5 | 5.2 | 6.4 |
| Back Pain | 4.3 | 2.1 | 5.3 |
| Dizziness | 3.7 | 2.6 | 5.3 |
| Flatulence | 1.6 | 3.7 | 5.3 |
| 24-Week Non-Controlled Double-Blind Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 45 mg + Insulin than in Patients Treated with ACTOS 30 mg + Insulin | |||
| % of Patients | |||
| ACTOS 30 mg + Insulin N=345 | ACTOS 45 mg + Insulin N=345 | ||
| Hypoglycemia | 43.5 | 47.8 | |
| Edema | 22.0 | 26.1 | |
| Weight Increased | 7.2 | 13.9 | |
| Urinary Tract Infection | 4.9 | 8.7 | |
| Diarrhea | 5.5 | 5.8 | |
| Back Pain | 3.8 | 6.4 | |
| Blood Creatine Phosphokinase Increased | 4.6 | 5.5 | |
| Sinusitis | 4.6 | 5.5 | |
| Hypertension | 4.1 | 5.5 | |
| Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of "edema." | |||
| Table 5. PROactive Trial: Incidence and Types of Adverse Events Reported in >5% of Patients Treated with ACTOS and More Commonly than Placebo | ||
|---|---|---|
| % of Patients | ||
| Placebo N=2633 | ACTOS N=2605 | |
| Hypoglycemia | 18.8 | 27.3 |
| Edema | 15.3 | 26.7 |
| Cardiac Failure | 6.1 | 8.1 |
| Pain in Extremity | 5.7 | 6.4 |
| Back Pain | 5.1 | 5.5 |
| Chest Pain | 5.0 | 5.1 |
| Mean duration of patient follow-up was 34.5 months. | ||
| Table 6. Treatment-Emergent Adverse Events of Congestive Heart Failure (CHF) | |||||
| Patients Treated with ACTOS or Placebo Added on to a Sulfonylurea | |||||
| Number (%) of Patients | |||||
| Placebo-Controlled Trial (16 weeks) | Non-ControlledDouble-Blind Trial (24 weeks) | ||||
| Placebo + Sulfonylurea N=187 | ACTOS 15 mg + Sulfonylurea N=184 | ACTOS 30 mg + Sulfonylurea N=189 | ACTOS 30 mg + Sulfonylurea N=351 | ACTOS 45 mg + Sulfonylurea N=351 | |
| At least one congestive heart failure event | 2 (1.1%) | 0 | 0 | 1 (0.3%) | 6 (1.7%) |
| Hospitalized | 2 (1.1%) | 0 | 0 | 0 | 2 (0.6%) |
| Patients Treated with ACTOS or Placebo Added on to Insulin | |||||
| Number (%) of Patients | |||||
| Placebo-Controlled Trial (16 weeks) | Non-Controlled Double-Blind Trial (24 weeks) | ||||
| Placebo + Insulin N=187 | ACTOS 15 mg + Insulin N=191 | ACTOS 30 mg + Insulin N=188 | ACTOS 30 mg + Insulin N=345 | ACTOS 45 mg + Insulin N=345 | |
| At least one congestive heart failure event | 0 | 2 (1.0%) | 2 (1.1%) | 3 (0.9%) | 5 (1.4%) |
| Hospitalized | 0 | 2 (1.0%) | 1 (0.5%) | 1 (0.3%) | 3 (0.9%) |
| Patients Treated with ACTOS or Placebo Added on to Metformin | |||||
| Number (%) of Patients | |||||
| Placebo-Controlled Trial (16 weeks) | Non-Controlled Double-Blind Trial (24 weeks) | ||||
| Placebo + Metformin N=160 | ACTOS 30 mg + Metformin N=168 | ACTOS 30 mg + Metformin N=411 | ACTOS 45 mg + Metformin N=416 | ||
| At least one congestive heart failure event | 0 | 1 (0.6%) | 0 | 1 (0.2%) | |
| Hospitalized | 0 | 1 (0.6%) | 0 | 1 (0.2%) | |
| Table 7. Treatment-Emergent Adverse Events of Congestive Heart Failure (CHF) in Patients with NYHA Class II or III Congestive Heart Failure Treated with ACTOS or Glyburide | ||
|---|---|---|
| Number (%) of Subjects | ||
| ACTOS N=262 | Glyburide N=256 | |
| Death due to cardiovascular causes (adjudicated) | 5 (1.9%) | 6 (2.3%) |
| Overnight hospitalization for worsening CHF (adjudicated) | 26 (9.9%) | 12 (4.7%) |
| Emergency room visit for CHF (adjudicated) | 4 (1.5%) | 3 (1.2%) |
| Patients experiencing CHF progression during study | 35 (13.4%) | 21 (8.2%) |
| Table 8. Treatment-Emergent Adverse Events of Congestive Heart Failure (CHF) in PROactive Trial | ||
|---|---|---|
| Number (%) of Patients | ||
| Placebo N=2633 | ACTOS N=2605 | |
| At least one hospitalized congestive heart failure event | 108 (4.1%) | 149 (5.7%) |
| Fatal | 22 (0.8%) | 25 (1.0%) |
| Hospitalized, nonfatal | 86 (3.3%) | 124 (4.7%) |
| Table 9. PROactive: Number of First and Total Events for Each Component within the Cardiovascular Composite Endpoint | ||||
|---|---|---|---|---|
| Cardiovascular Events | Placebo N=2633 | ACTOS N=2605 | ||
| First Events n (%) | Total events n | First Events n (%) | Total events n | |
| Any event | 572 (21.7) | 900 | 514 (19.7) | 803 |
| All-cause mortality | 122 (4.6) | 186 | 110 (4.2) | 177 |
| Nonfatal myocardial infarction (MI) | 118 (4.5) | 157 | 105 (4.0) | 131 |
| Stroke | 96 (3.6) | 119 | 76 (2.9) | 92 |
| Acute coronary syndrome | 63 (2.4) | 78 | 42 (1.6) | 65 |
| Cardiac intervention (CABG/PCI) | 101 (3.8) | 240 | 101 (3.9) | 195 |
| Major leg amputation | 15 (0.6) | 28 | 9 (0.3) | 28 |
| Leg revascularization | 57 (2.2) | 92 | 71 (2.7) | 115 |
| CABG = coronary artery bypass grafting; PCI = percutaneous intervention | ||||
| Table 10. Weight Changes (kg) from Baseline During Randomized, Double-Blind Clinical Trials | |||||
|---|---|---|---|---|---|
| Control Group (Placebo) | ACTOS 15 mg | ACTOS 30 mg | ACTOS 45 mg | ||
| Median (25th/75th percentile) | Median (25th/75th percentile) | Median (25th/75th percentile) | Median (25th/75th percentile) | ||
| Monotherapy (16 to 26 weeks) | -1.4 (-2.7/0.0) N=256 | 0.9 (-0.5/3.4) N=79 | 1.0 (-0.9/3.4) N=188 | 2.6 (0.2/5.4) N=79 | |
| Combination Therapy (16 to 24 weeks) | Sulfonylurea | -0.5 (-1.8/0.7) N=187 | 2.0 (0.2/3.2) N=183 | 3.1 (1.1/5.4) N=528 | 4.1 (1.8/7.3) N=333 |
| Metformin | -1.4 (-3.2/0.3) N=160 | N/A | 0.9 (-1.3/3.2) N=567 | 1.8 (-0.9/5.0) N=407 | |
| Insulin | 0.2 (-1.4/1.4) N=182 | 2.3 (0.5/4.3) N=190 | 3.3 (0.9/6.3) N=522 | 4.1 (1.4/6.8) N=338 | |
| Table 11. Median Change in Body Weight in Patients Treated with ACTOS Versus Patients Treated with Placebo During the Double-Blind Treatment Period in the PROactive Trial | ||
| Placebo | ACTOS | |
| Median(25th/75thpercentile) | Median(25th/75thpercentile) | |
| Change from baseline to final visit (kg) | -0.5 (-3.3, 2.0)N=2581 | +3.6 (0.0, 7.5)N=2560 |
| Note: Median exposure for both ACTOS and Placebo was 2.7 years. | ||
| Table 12. Adverse Events of Edema in Patients Treated with ACTOS | |||||
|---|---|---|---|---|---|
| Number (%) of Patients | |||||
| Placebo | ACTOS 15 mg | ACTOS 30 mg | ACTOS 45 mg | ||
| Monotherapy (16 to 26 weeks) | 3 (1.2%) N=259 | 2 (2.5%) N= 81 | 13 (4.7%) N= 275 | 11 (6.5%) N=169 | |
| Combined Therapy (16 to 24 weeks) | Sulfonylurea | 4 (2.1%) N=187 | 3 (1.6%) N=184 | 61 (11.3%) N=540 | 81 (23.1%) N=351 |
| Metformin | 4 (2.5%) N=160 | N/A | 34 (5.9%) N=579 | 58 (13.9%) N=416 | |
| Insulin | 13 (7.0%) N=187 | 24 (12.6%) N=191 | 109 (20.5%) N=533 | 90 (26.1%) N=345 | |
| Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of "edema." | |||||
| Table 13. Adverse Events of Edema in Patients in the PROactive Trial | |
|---|---|
| Number (%) of Patients | |
| Placebo N=2633 | ACTOS N=2605 |
| 419 (15.9%) | 712 (27.3%) |
| Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of "edema." | |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Limited data with ACTOS in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations]. In animal reproduction studies, no adverse developmental effects were observed when pioglitazone was administered to pregnant rats and rabbits during organogenesis at exposures up to 5- and 35-times the 45 mg clinical dose, respectively, based on body surface area [see Data].
The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20-25% in women with a HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, still birth and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia related morbidity.
Data Animal Data Pioglitazone administered to pregnant rats during organogenesis did not cause adverse developmental effects at a dose of 20 mg/kg (~5-times the 45 mg clinical dose), but delayed parturition and reduced embryofetal viability at 40 and 80 mg/kg, or ≥9-times the 45 mg clinical dose, by body surface area. In pregnant rabbits administered pioglitazone during organogenesis, no adverse developmental effects were observed at 80 mg/kg (~35-times the 45 mg clinical dose), but reduced embryofetal viability at 160 mg/kg, or ~69-times the 45 mg clinical dose, by body surface area.
When pregnant rats received pioglitazone during late gestation and lactation, delayed postnatal development, attributed to decreased body weight, occurred in offspring at maternal doses of 10 mg/kg and above or ≥2 times the 45 mg clinical dose, by body surface area.
Mechanism of action
12.1 Mechanism of Action ACTOS is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. ACTOS decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue.
Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARγ nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism.
In animal models of diabetes, pioglitazone reduces the hyperglycemia, hyperinsulinemia, and hypertriglyceridemia characteristic of insulin-resistant states such as type 2 diabetes. The metabolic changes produced by pioglitazone result in increased responsiveness of insulin-dependent tissues and are observed in numerous animal models of insulin resistance.
Because pioglitazone enhances the effects of circulating insulin (by decreasing insulin resistance), it does not lower blood glucose in animal models that lack endogenous insulin.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Clinical studies demonstrate that ACTOS improves insulin sensitivity in insulin-resistant patients. ACTOS enhances cellular responsiveness to insulin, increases insulin-dependent glucose disposal and improves hepatic sensitivity to insulin. In patients with type 2 diabetes, the decreased insulin resistance produced by ACTOS results in lower plasma glucose concentrations, lower plasma insulin concentrations, and lower HbA1c values.
In controlled clinical trials, ACTOS had an additive effect on glycemic control when used in combination with a sulfonylurea, metformin, or insulin [see Clinical Studies (14.2)]. Patients with lipid abnormalities were included in clinical trials with ACTOS. Overall, patients treated with ACTOS had mean decreases in serum triglycerides, mean increases in HDL cholesterol, and no consistent mean changes in LDL and total cholesterol.
There is no conclusive evidence of macrovascular benefit with ACTOS [see Warnings and Precautions (5.8) and Adverse Reactions (6.1)]. In a 26-week, placebo-controlled, dose-ranging monotherapy study, mean serum triglycerides decreased in the 15 mg, 30 mg, and 45 mg ACTOS dose groups compared to a mean increase in the placebo group.
Mean HDL cholesterol increased to a greater extent in patients treated with ACTOS than in the placebo-treated patients. There were no consistent differences for LDL and total cholesterol in patients treated with ACTOS compared to placebo (see Table 14). Table 14. Lipids in a 26-Week Placebo-Controlled Monotherapy Dose-Ranging Study Placebo ACTOS 15 mg Once Daily ACTOS 30 mg Once Daily ACTOS 45 mg Once Daily Triglycerides (mg/dL) N=79 N=79 N=84 N=77 Baseline (mean) 263 284 261 260 Percent change from baseline (adjusted mean Adjusted for baseline, pooled center, and pooled center by treatment interaction) 4.8% -9.0% p<0.05 versus placebo -9.6% -9.3% HDL Cholesterol (mg/dL) N=79 N=79 N=83 N=77 Baseline (mean) 42 40 41 41 Percent change from baseline (adjusted mean) 8.1% 14.1% 12.2% 19.1% LDL Cholesterol (mg/dL) N=65 N=63 N=74 N=62 Baseline (mean) 139 132 136 127 Percent change from baseline (adjusted mean) 4.8% 7.2% 5.2% 6.0% Total Cholesterol (mg/dL) N=79 N=79 N=84 N=77 Baseline (mean) 225 220 223 214 Percent change from baseline (adjusted mean) 4.4% 4.6% 3.3% 6.4% In the two other monotherapy studies (16 weeks and 24 weeks) and in combination therapy studies with sulfonylurea (16 weeks and 24 weeks), metformin (16 weeks and 24 weeks) or insulin (16 weeks and 24 weeks), the results were generally consistent with the data above.
Pharmacokinetics
Urinary 6ß-hydroxycortisol/cortisol ratios measured in patients treated with ACTOS showed that pioglitazone is not a strong CYP3A4 enzyme inducer.
Excretion and Elimination Following oral administration, approximately 15% to 30% of the pioglitazone dose is recovered in the urine.
Renal elimination of pioglitazone is negligible, and the drug is excreted primarily as metabolites and their conjugates.
It is presumed that most of the oral dose is excreted into the bile either unchanged or as metabolites and eliminated in the feces.
The mean serum half-life (t 1/2 ) of pioglitazone and its metabolites (M-III and M-IV) range from three to seven hours and 16 to 24 hours, respectively.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Following once-daily administration of ACTOS, steady-state serum concentrations of both pioglitazone and its major active metabolites, M-III (keto derivative of pioglitazone) and M-IV (hydroxyl derivative of pioglitazone), are achieved within seven days. At steady-state, M-III and M-IV reach serum concentrations equal to or greater than that of pioglitazone.
At steady-state, in both healthy volunteers and patients with type 2 diabetes, pioglitazone comprises approximately 30% to 50% of the peak total pioglitazone serum concentrations (pioglitazone plus active metabolites) and 20% to 25% of the total AUC. C max, AUC, and trough serum concentrations (C min) for pioglitazone and M-III and M-IV, increased proportionally with administered doses of 15 mg and 30 mg per day.
Absorption Following oral administration of pioglitazone, T max of pioglitazone was within two hours. Food delays the T max to three to four hours but does not alter the extent of absorption (AUC). Distribution The mean apparent volume of distribution (Vd/F) of pioglitazone following single-dose administration is 0.63 ± 0.41 (mean ± SD) L/kg of body weight.
Pioglitazone is extensively protein bound (>99%) in human serum, principally to serum albumin. Pioglitazone also binds to other serum proteins, but with lower affinity. M-III and M-IV are also extensively bound (>98%) to serum albumin. Metabolism Pioglitazone is extensively metabolized by hydroxylation and oxidation; the metabolites also partly convert to glucuronide or sulfate conjugates.
Metabolites M-III and M-IV are the major circulating active metabolites in humans. In vitro data demonstrate that multiple CYP isoforms are involved in the metabolism of pioglitazone, which include CYP2C8 and, to a lesser degree, CYP3A4 with additional contributions from a variety of other isoforms including the mainly extrahepatic CYP1A1.
In vivo study of pioglitazone in combination with gemfibrozil, a strong CYP2C8 inhibitor, showed that pioglitazone is a CYP2C8 substrate [see Dosage and Administration (2.3) and Drug Interactions (7)]. Urinary 6ß-hydroxycortisol/cortisol ratios measured in patients treated with ACTOS showed that pioglitazone is not a strong CYP3A4 enzyme inducer.
Excretion and Elimination Following oral administration, approximately 15% to 30% of the pioglitazone dose is recovered in the urine. Renal elimination of pioglitazone is negligible, and the drug is excreted primarily as metabolites and their conjugates. It is presumed that most of the oral dose is excreted into the bile either unchanged or as metabolites and eliminated in the feces.
The mean serum half-life (t 1/2) of pioglitazone and its metabolites (M-III and M-IV) range from three to seven hours and 16 to 24 hours, respectively. Pioglitazone has an apparent clearance, CL/F, calculated to be five to seven L/hr. Renal Impairment The serum elimination half-life of pioglitazone, M-III, and M-IV remains unchanged in patients with moderate (creatinine clearance [CLcr] 30 to 50 mL/min) and severe (CLcr <30 mL/min) renal impairment when compared to subjects with normal renal function.
Therefore, no dose adjustment in patients with renal impairment is required. Hepatic Impairment Compared with healthy controls, subjects with impaired hepatic function (Child-Turcotte-Pugh Grade B/C) have an approximate 45% reduction in pioglitazone and total pioglitazone (pioglitazone, M-III, and M-IV) mean C max but no change in the mean AUC values.
Therefore, no dose adjustment in patients with hepatic impairment is required. There are postmarketing reports of liver failure with ACTOS and clinical trials have generally excluded patients with serum ALT >2.5 times the upper limit of the reference range. Use caution in patients with liver disease [see Warnings and Precautions (5.3)].
Geriatric Patients In healthy elderly subjects, C max of pioglitazone was not significantly different, but AUC values were approximately 21% higher than those achieved in younger subjects. The mean t 1/2 of pioglitazone was also prolonged in elderly subjects (about ten hours) as compared to younger subjects (about seven hours).
These changes were not of a magnitude that would be considered clinically relevant. Pediatric Patients Safety and efficacy of pioglitazone in pediatric patients have not been established. ACTOS is not recommended for use in pediatric patients [see Use in Specific Populations (8.4)]. Gender The mean C max and AUC values of pioglitazone were increased 20% to 60% in women compared to men.
In controlled clinical trials, HbA1c decreases from baseline were generally greater for females than for males (average mean difference in HbA1c 0.5%). Because therapy should be individualized for each patient to achieve glycemic control, no dose adjustment is recommended based on gender alone. Ethnicity Pharmacokinetic data among various ethnic groups are not available.
Drug-Drug Interactions Table 15. Effect of Pioglitazone Coadministration on Systemic Exposure of Other Drugs Coadministered Drug Pioglitazone Dosage Regimen (mg) Daily for 7 days unless otherwise noted Name and Dose Regimens Change in AUC % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively Change in C max 45 mg (N = 12) Warfarin Pioglitazone had no clinically significant effect on prothrombin time Daily loading then maintenance doses based PT and INR values Quick's Value = 35 ± 5% R-Warfarin ↓3% R-Warfarin ↓2% S-Warfarin ↓1% S-Warfarin ↑1% 45 mg (N = 12) Digoxin 0.200 mg twice daily (loading dose) then 0.250 mg daily (maintenance dose, 7 days) ↑15% ↑17% 45 mg daily for 21 days (N = 35) Oral Contraceptive [Ethinyl Estradiol (EE) 0.035 mg plus Norethindrone (NE) 1 mg] for 21 days EE ↓11% EE ↓13% NE ↑3% NE ↓7% 45 mg (N = 23) Fexofenadine 60 mg twice daily for 7 days ↑30% ↑37% 45 mg (N = 14) Glipizide 5 mg daily for 7 days ↓3% ↓8% 45 mg daily for 8 days (N = 16) Metformin 1000 mg single dose on Day 8 ↓3% ↓5% 45 mg (N = 21) Midazolam 7.5 mg single dose on Day 15 ↓26% ↓26% 45 mg (N = 24) Ranitidine 150 mg twice daily for 7 days ↑1% ↓1% 45 mg daily for 4 days (N = 24) Nifedipine ER 30 mg daily for 4 days ↓13% ↓17% 45 mg (N = 25) Atorvastatin Ca 80 mg daily for 7 days ↓14% ↓23% 45 mg (N = 22) Theophylline 400 mg twice daily for 7 days ↑2% ↑5% Table 16.
Effect of Coadministered Drugs on Pioglitazone Systemic Exposure Coadministered Drug and Dosage Regimen Pioglitazone Dose Regimen (mg) Daily for 7 days unless otherwise noted Change in AUC Mean ratio (with/without coadministered drug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively Change in C max Gemfibrozil 600 mg twice daily for 2 days (N = 12) 15 mg single dose ↑3.2-fold The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1)] ↑6% Ketoconazole 200 mg twice daily for 7 days (N = 28) 45 mg ↑34% ↑14% Rifampin 600 mg daily for 5 days (N = 10) 30 mg single dose ↓54% ↓5% Fexofenadine 60 mg twice daily for 7 days (N = 23) 45 mg ↑1% 0% Ranitidine 150 mg twice daily for 4 days (N = 23) 45 mg ↓13% ↓16% Nifedipine ER 30 mg daily for 7 days (N = 23) 45 mg ↑5% ↑4% Atorvastatin Ca 80 mg daily for 7 days (N = 24) 45 mg ↓24% ↓31% Theophylline 400 mg twice daily for 7 days (N = 22) 45 mg ↓4% ↓2% Topiramate 96 mg twice daily for 7 days Indicates duration of concomitant administration with highest twice-daily dose of topiramate from Day 14 onwards over the 22 days of study (N = 26) 30 mg ↓15% Additional decrease in active metabolites; 60% for M-III and 16% for M-IV 0%
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Actos · Takeda Pharmaceuticals America, Inc. [US FDA-approved label, version 20, March 28, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
